Vol 6, Supplement 9 (December 2017): Translational Cancer Research


Exosome targeted therapy—a step in the future
Marie-Claude Gingras, Richard Julian Jones
In vitro three-dimensional culture of hepatocellular carcinoma to measure prognosis and responsiveness to chemotherapeutic agents
Mengyun Peng, Jing Wang, Yongxiang Yi, Yanhui Liu, Xiaolong Qi
Therapeutic targeting of oncogenic KRAS in pancreatic cancer by engineered exosomes
Theresa L. Whiteside
Living-donor liver transplantation for hepatocellular carcinoma in Japan and Korea
Yasuhiko Sugawara
Small hepatocellular carcinoma: which criteria for liver transplantation?
Giovanni Battista Levi Sandri
Two’s company, three’s a crowd: the continuing saga of threedrug regimens for extensive-stage small cell lung cancer
Frank Weinberg, Gregory P. Kalemkerian
Expanding the portfolio of anaplastic lymphoma kinase inhibitors for anaplastic lymphoma kinase-rearranged lung cancers
Fernando C. Santini, Renata M. Salhab, Shorabh Sharma, Alexander Drilon
Dickkopf-1 helps metastasis by immune evasion
Atsuko Deguchi, Yoshiro Maru
Glycation and hepatocellular carcinoma: where we stand
Nadia Panera, Anna Alisi
Deletion of tumor progression locus two attenuates alcoholinduced
Tao Han, Guanggang Li, Zhendong Zheng
Have we considered all barriers to mammalian target of rapamycin inhibition as treatment for diffuse intrinsic pontine glioma?
Mark C. de Gooijer, Olaf van Tellingen
How can we predict hepatic insufficiency after resection of colorectal liver metastases?
Yo-Ichi Yamashita, Hideo Baba
TIC10/ONC201—a potential therapeutic in glioblastoma
Georg Karpel-Massler, Markus D. Siegelin
The evolving role of molecular profiling in prostate cancer: basal and luminal subtyping transcends tissue of origin
Omar Y. Mian, Rahul D. Tendulkar, Mohamed E. Abazeed
Postoperative capecitabine in breast cancer neoadjuvant failures
Richard E. Kast
Crosstalk between circular RNAs and microRNAs in tumorigenesis
Xiaoyun He, Gaoyan Kuang, Chunlin Ou, Pengfei Cao
Multifactorial regulators of tumor programmed death-ligand 1 (PD-L1) response
R. Dixon Dorand, Agne Petrosiute, Alex Y. Huang
A non-coding RNA axis guides TGF-β-induced gemcitabine chemoresistance
Hardik R. Mody, Rajgopal Govindarajan
From transcriptional noise to modulator of the TGFB1 pathway, a player in the development of chemoresistance: lncRNA-LET
Heba A. Fanous, Travis B. Sullivan, Kimberly Rieger-Christ
Association between radiosensitivity and molecular subtypes in patients with early-stage breast cancer and lymph node-negative status
Sung-Hsin Kuo, Chiun-Sheng Huang
A tiny but crucial player bridging microbes and colonic carcinogenesis
Motoyuki Otsuka, Rei Ishibashi, Eri Tanaka, Takahiro Seimiya, Tatsunori Suzuki, Kazuma Sekiba, Mari Yamagami, Motoko Ohno, Takahiro Kishikawa, Kazuhiko Koike
Fatigue following head and neck cancer radiotherapy: an unrecognized side effect of modern radiotherapy techniques?
Rosie Twomey, S. Nicole Culos-Reed, Guillaume Y. Millet, Harold Lau
RAD6: a new target to overcome platinum resistance in ovarian cancer?
Francesca Maddalena, Giacomo Lettini, Franca Esposito, Matteo Landriscina
Serrated polyposis: the problem of definition and its relationship to the population at risk for syndrome-related colorectal cancer
Joanne P. Young, Timothy J. Price, Susan Parry
Immune checkpoint inhibition in small cell lung cancer: a key to reach an unmet need?
Francesco Gelsomino, Alessandro Leonetti, Karim Rihawi, Francesca Sperandi, Laura Casolari, Barbara Melotti, Michelangelo Fiorentino, Andrea Ardizzoni


This supplement was published without any sponsorship or funding.